Literature DB >> 16331266

A peptide aptamer to antagonize BCL-6 function.

A Chattopadhyay1, S A Tate, R W Beswick, S D Wagner, P Ko Ferrigno.   

Abstract

BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein-protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Notably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. We also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 overexpressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331266     DOI: 10.1038/sj.onc.1209252

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Synthesis and selection of de novo proteins that bind and impede cellular functions of an essential mycobacterial protein.

Authors:  Alka Rao; Geeta Ram; Adesh Kumar Saini; Reena Vohra; Krishan Kumar; Yogendra Singh; Anand Ranganathan
Journal:  Appl Environ Microbiol       Date:  2006-12-22       Impact factor: 4.792

2.  Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.

Authors:  Alexandru F Ghetu; Connie M Corcoran; Leandro Cerchietti; Vivian J Bardwell; Ari Melnick; Gilbert G Privé
Journal:  Mol Cell       Date:  2008-02-15       Impact factor: 17.970

3.  Structure of the wild-type human BCL6 POZ domain.

Authors:  Mark A Stead; Gareth O Rosbrook; Jonathan M Hadden; Chi H Trinh; Stephen B Carr; Stephanie C Wright
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-11-28

Review 4.  B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Weimin Ci; Jose M Polo; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

Review 5.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05

Review 6.  Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function.

Authors:  Benjamin Gibert; Stéphanie Simon; Valeriya Dimitrova; Chantal Diaz-Latoud; André-Patrick Arrigo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-03-25       Impact factor: 6.237

7.  Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant.

Authors:  Toni Hoffmann; Lukas Kurt Josef Stadler; Michael Busby; Qifeng Song; Anthony T Buxton; Simon D Wagner; Jason J Davis; Paul Ko Ferrigno
Journal:  Protein Eng Des Sel       Date:  2010-02-23       Impact factor: 1.650

8.  Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation.

Authors:  Rochana D Wickramasinghe; Paul Ko Ferrigno; Christian Roghi
Journal:  BMC Cell Biol       Date:  2010-07-23       Impact factor: 4.241

Review 9.  Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.

Authors:  James J Steinhardt; Ronald B Gartenhaus
Journal:  Clin Cancer Res       Date:  2012-06-27       Impact factor: 12.531

10.  Bcl6 is expressed in neuroblastoma: tumor cell type-specific expression predicts outcome.

Authors:  Aghiad Chamdin; Jason A Jarzembowski; Chitra Subramanian; Rork Kuick; Julia Shin-Jung Lee; Roland Ps Kwok; Valerie P Castle; Anthony W Opipari
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.